Pylarify

Chemical Namepiflufolastat F 18
Dosage FormInjection (intravenous; (1 mCi/mL-80 mCi/mL)
Drug ClassRadioactive diagnostic agents
SystemMale reproductive
CompanyProgenics Pharmaceuticals, Inc.
Approval Year2021

Indication

  • Indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy.
  • Indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Last updated on 10/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pylarify (piflufolastat F 18) Prescribing Information2021Progenics Pharmaceuticals, Inc., Billerica, MA